5-METHOXY-N,N-DIISOPROPYLTRYPTAMINE
(Street Names: Foxy, or Foxy methoxy)
August 2007 DEA/OD/ODE
Introduction:
5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) is a tryptamine derivative and shares many similarities with schedule I tryptamine hallucinogens such as alpha-ethyltryptamine, N,N-dimethyltryptamine, N,N-diethyltryptamine, bufotenine, psilocybin and psilocin. Since 1999, there has been a growing popularity of 5-MeO-DIPT among drug abusers. This substance is abused for its hallucinogenic effects.
Licit Uses:
5-MeO-DIPT has no approved medical uses in the United States.
Chemistry/Pharmacology:
5-MeO-DIPT is a tryptamine derivative. The hydrochloride salt of 5-MeO-DIPT is a white crystalline powder. In animal behavioral studies, 5-MeO-DIPT has been shown to produce behavioral effects that are substantially similar to those of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) and lysergic acid diethylamide (LSD), both schedule I hallucinogens.
In humans, 5-MeO-DIPT elicits subjective effects including hallucinations similar to those produced by several schedule I hallucinogens such as 2C-B and 4-ethyl-2,5-dimethoxyphenyl-isopropylamine (DOET). The threshold dose of 5-MeO-DIPT to produce psychoactive effects is 4 mg, while effective doses range from 6 to 20 mg. 5-MeO-DIPT produces effects with an onset of 20 to 30 minutes and with peak effects occurring between 1 to 1.5 hours after administration. Effects last about 3 to 6 hours. Initial effects include mild nausea, muscular hyperreflexia, and dilation of pupils. Other effects include relaxation associated with emotional enhancement, talkativeness and behavioral disinhibition. High doses of 5-MeO-DIPT produce abstract eyes-closed imagery. 5-MeO-DIPT alters sensory perception and judgment and can pose serious health risks to the user and the general public. Abuse of 5-MeO-DIPT led to at least one emergency department admission.
Illicit Uses:
5-MeO-DIPT is abused for its hallucinogenic-like effects and is used as a substitute for MDMA. It is often administered orally as either powder, tablets or capsules at doses ranging from 6-20 mg. Other routes of administration include smoking and snorting. Tablets often bear imprints commonly seen on MDMA tablets (spider and alien head logos) and vary in color. Powder in capsules was found to vary in colors.
User Population:
Youth and young adults are the main abusers of 5-MeO-DIPT.
Illicit Distribution:
According to the System to Retrieve Information from Drug Evidence (STRIDE) data, since 2001, DEA forensic laboratories analyzed 73 drug exhibits from 38 law enforcement cases pertaining to the trafficking, distribution and abuse of 5-MeO-DIPT. The analyzed exhibits comprised of about 12,207 tablets, 579 capsules, and 6,537.93 gm powder.
According to National Forensic Laboratory Information System (NFLIS), state and local forensic laboratories analyzed 43 5-MeO-DIPT drug items from 36 different law enforcement cases during 1999 through 2006.
According to STRIDE and NFLIS, 5-MeO-DIPT has been encountered in a number of states including Arizona, Arkansas, California, Delaware, District of Columbia, Idaho, Illinois, Indiana, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Minnesota, Nevada, New Jersey, New Mexico, New York, Oregon, Pennsylvania, Texas, Virginia, Washington and Wisconsin. 5-MeO-DIPT has been illicitly available from United States and foreign chemical companies and from individuals through the Internet. There is some evidence of the attempted clandestine production of 5-MeO-DIPT.
Control Status:
The Drug Enforcement Administration (DEA) placed 5-MeO-DIPT temporarily in schedule I of the Controlled Substances Act (CSA) on April 4, 2003, pursuant to the temporary scheduling provisions of the CSA (68 FR 16427). On September 29, 2004, 5-MeO-DIPT was controlled as schedule I substance under the CSA (69 FR 58050).
Volgens mij.... 
